Depression, Unipolar Clinical Trial
— DELAYOfficial title:
Effects of Cognitive Behavioural Therapy and Bright Light Therapy in Youth With Unipolar Depression and Evening Chronotype: An Assessor-blind Parallel-group Randomised Controlled Trial
The goal of this prospective randomised controlled trial is to examine the effects of cognitive behavioural therapy and bright light therapy in youths with unipolar depression and evening chronotype. The main questions it aims to answer are: 1. What is the efficacy of CBT-D and CBT-D plus bright light therapy in reducing depression severity in adolescents with depression and eveningness? 2. What are the effects of CBT-D and CBT-D plus bright light therapy on the subjective and objective sleep and circadian measures, as well as the quality of life, daytime symptoms, and functioning (e.g., sleepiness, fatigue)? Participants will participate in 8 weekly group sessions of CBT-D intervention based on the well-established CBT elements for treating depression. Concurrently participants will also be asked to wear a portable light device at home for 30 minutes daily for seven weeks, starting from the second week of the group intervention. Participants in the CBT-D only group will receive a placebo light via the device, whereas participants in the CBT-D plus light therapy group will receive the active bright light via the device.
Status | Recruiting |
Enrollment | 162 |
Est. completion date | October 20, 2026 |
Est. primary completion date | December 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 12 Years to 20 Years |
Eligibility | Inclusion Criteria: 1. Chinese aged 12-20 years old. 2. Written informed consent of participation into the study is given by the participant and his/her parent or guardian (for those aged under 18). 3. Being able to comply with the study protocol. 4. Having a DSM-5 diagnosis of depressive disorders. 5. Having a score of = 40 on Children's Depression Rating Scale (CDRS-R). 6. Having a score of = 41 on Horne-Östberg Morning-Eveningness Questionnaire (MEQ; classified as evening chronotype). 7. Having a sleep onset time of 11:15pm or later for 12 year olds, 11:30pm or later for 13-14 year olds, and 12:00pm or later for 15-20 years at least 3 nights per week in the past 3 months. Exclusion Criteria: 1. A current diagnosis of substance abuse or dependence; a current or past history of manic or hypomanic episode, schizophrenia spectrum disorders, neurodevelopmental disorders, organic mental disorders, or intellectual disabilities. 2. Initiation of and change of medication that may interfere with circadian rhythm within past 3 months (e.g., lithium, exogenous melatonin, melatonergic antidepressants). 3. In the opinion of the research clinician, having a clinically significant suicidality (presence of suicidal ideation with a plan or an attempt). 4. Having been enrolled in any other clinical trial investigational products within one month at the entry of the study. 5. Initiation of or change in antidepressant medication within past 3 months. 6. Having been or is currently receiving any structured psychotherapy. 7. With hearing or speech deficit. 8. Night shift worker. 9. Trans-meridian flight in the past 1 month and during intervention. 10. Presence of an eye disease (e.g., retinal blindness, severe cataract, glaucoma). |
Country | Name | City | State |
---|---|---|---|
Hong Kong | Sleep Research Clinic & Laboratory, Department of Psychology, The University of Hong Kong | Hong Kong |
Lead Sponsor | Collaborator |
---|---|
The University of Hong Kong | Chinese University of Hong Kong |
Hong Kong,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Assessor-rated Depressive Symptoms | Children's Depression Rating Scale (CDRS-R) is a 17-item rating scale based on a semi-structured interview with children. Possible scores range from 17 to 113, with higher scores indicating severer depressive symptoms. | Baseline and one-week post-treatment/Week 9 for all participants, and post-treatment 1-month follow-up and post-treatment 6-month follow-up for the participants in the treatment groups | |
Secondary | Change of Self-report Depressive Symptoms | Beck's Depression Inventory (BDI-II) is a 21-item self-report rating scale measuring depression symptoms. Possible scores range from 0 to 62, with higher scores indicating more severe depressive symptoms. | Baseline and one-week post-treatment/Week 9 for all participants, and post-treatment 1-month follow-up and post-treatment 6-month follow-up for the participants in the treatment groups | |
Secondary | Change of Suicidal Ideation | The Beck's Suicide Ideation Scale (BSSI) is a 19-item self-report rating scale measuring suicide ideation. Possible scores range from 0 to 38, with higher scores indicating higher suicide intention. | Baseline and one-week post-treatment/Week 9 for all participants, and post-treatment 1-month follow-up and post-treatment 6-month follow-up for the participants in the treatment groups | |
Secondary | Change in Self-Report Chronotype Measures | Munich Chronotype Questionnaire (MCTQ) is a self-report measures of sleeping patterns during weekdays and weekends separately. The Mid-Sleep Time (MSF/MSFsc) are used to as an indicator of chronotype, where individuals with earlier mid-sleep time reflect a morning chronotype and later mid-sleep time reflect an evening chronotype. | Baseline and one-week post-treatment/Week 9 for all participants, and post-treatment 1-month follow-up and post-treatment 6-month follow-up for the participants in the treatment groups | |
Secondary | Change in Self-Report Circadian Typology | The Morningness-Eveningness Questionnaire (MEQ) is a 19-item self-report rating scale measuring circadian preference (typology). Possible scores range from 16 to 89, with lower scores indicating preference towards eveningness. Based on the conventional cut off, having a MEQ score of 16-41 is considered eveningness. | Baseline and one-week post-treatment/Week 9 for all participants, and post-treatment 1-month follow-up and post-treatment 6-month follow-up for the participants in the treatment groups | |
Secondary | Change in Insomnia Symptoms | Insomnia Severity Index (ISI) is a 5-item self-rated scale. Possible scores range from 0 to 20, with higher scores indicating higher insomnia severity. | Baseline and one-week post-treatment/Week 9 for all participants, and post-treatment 1-month follow-up and post-treatment 6-month follow-up for the participants in the treatment groups | |
Secondary | Change in Sleep Quality | Pittsburgh Sleep Quality Index (PSQI) is a self-rated scale consisting of 19 questions. All items are combined to form seven component scores on different aspects of sleep quality, each of which ranges from 0 to 3 points with higher scores representing more sleep disturbance. The seven component scores are added to one global score, which ranges from 0 to 21, with higher scores indicating more difficulties with sleep. | Baseline and one-week post-treatment/Week 9 for all participants, and post-treatment 1-month follow-up and post-treatment 6-month follow-up for the participants in the treatment groups | |
Secondary | Change in Total Sleep Time (TST) measured by sleep diary | Daily sleep diary for seven consecutive days. Total sleep time (hours) was estimated by averaging the recorded days. | Baseline and one-week post-treatment/Week 9 for all participants, and post-treatment 1-month follow-up and post-treatment 6-month follow-up for the participants in the treatment groups | |
Secondary | Change in Sleep Onset Latency (SOL) measured by sleep diary | Daily sleep diary for seven consecutive days. Sleep onset latency (minutes) was estimated by averaging the recorded days. | Baseline and one-week post-treatment/Week 9 for all participants, and post-treatment 1-month follow-up and post-treatment 6-month follow-up for the participants in the treatment groups | |
Secondary | Change in Wake After Sleep Onset (WASO) measured by sleep diary | Daily sleep diary for seven consecutive days. Wake after sleep onset (minutes) was estimated by averaging the recorded days. | Baseline and one-week post-treatment/Week 9 for all participants, and post-treatment 1-month follow-up and post-treatment 6-month follow-up for the participants in the treatment groups | |
Secondary | Change in Sleep Efficiency (SE) measured by sleep diary | Daily sleep diary for seven consecutive days. Sleep efficiency (in percentage, calculated by total sleep time divided by total time in bed) was estimated by averaging the recorded days. | Baseline and one-week post-treatment/Week 9 for all participants, and post-treatment 1-month follow-up and post-treatment 6-month follow-up for the participants in the treatment groups | |
Secondary | Change in Total Sleep Time (TST) measured by actigraphy | Actigraphy assessment for seven consecutive days. Total sleep time (hours) was estimated by averaging the recorded days. | Baseline and one-week post-treatment/Week 9 for all participants, and post-treatment 1-month follow-up and post-treatment 6-month follow-up for the participants in the treatment groups | |
Secondary | Change in Sleep Onset Latency (SOL) measured by actigraphy | Actigraphy assessment for seven consecutive days. Sleep onset latency (minutes) was estimated by averaging the recorded days. | Baseline and one-week post-treatment/Week 9 for all participants, and post-treatment 1-month follow-up and post-treatment 6-month follow-up for the participants in the treatment groups | |
Secondary | Change in Wake After Sleep Onset (WASO) measured by actigraphy | Actigraphy assessment for seven consecutive days. Wake after sleep onset (minutes) was estimated by averaging the recorded days. | Baseline and one-week post-treatment/Week 9 for all participants, and post-treatment 1-month follow-up and post-treatment 6-month follow-up for the participants in the treatment groups | |
Secondary | Change in Sleep Efficiency (SE) measured by actigraphy | Actigraphy assessment for seven consecutive days. Sleep efficiency (in percentage, calculated by total sleep time divided by total time in bed) was estimated by averaging the recorded days. | Baseline and one-week post-treatment/Week 9 for all participants, and post-treatment 1-month follow-up and post-treatment 6-month follow-up for the participants in the treatment groups | |
Secondary | Change in Actigraphic Circadian Measures - L5 computed by nonparametric circadian rhythm analysis | Actigraphic assessment for seven consecutive days. The start times and average activity of L5 (i.e., five hours of least activity within a 24-hour period) is computed by the nonparametric circadian rhythm analysis. | Baseline and one-week post-treatment/Week 9 for all participants, and post-treatment 1-month follow-up and post-treatment 6-month follow-up for the participants in the treatment groups | |
Secondary | Change in Actigraphic Circadian Measures - M10 computed by nonparametric circadian rhythm analysis | Actigraphic assessment for seven consecutive days. The start times and average activity of M10 (i.e., 10 hours of maximal activity within a 24-hour period) is computed by the nonparametric circadian rhythm analysis. | Baseline and one-week post-treatment/Week 9 for all participants, and post-treatment 1-month follow-up and post-treatment 6-month follow-up for the participants in the treatment groups | |
Secondary | Change in Actigraphic Circadian Measures - acrophase computed by cosinor analysis | Actigraphic assessment for seven consecutive days. The acrophase (defined as time of maximum activity express as clock time) is computed by cosinor analysis. | Baseline and one-week post-treatment/Week 9 for all participants, and post-treatment 1-month follow-up and post-treatment 6-month follow-up for the participants in the treatment groups | |
Secondary | Change in Actigraphic Circadian Measures - amplitude computed by cosinor analysis | Actigraphic assessment for seven consecutive days. The amplitude (defined as the differences in distance from the peak to the nadir) is computed by cosinor analysis. | Baseline and one-week post-treatment/Week 9 for all participants, and post-treatment 1-month follow-up and post-treatment 6-month follow-up for the participants in the treatment groups | |
Secondary | Change in Actigraphic Circadian Measures - MESOR computed by cosinor analysis | Actigraphic assessment for seven consecutive days. The MESOR (defined as the mean activity level) is computed by cosinor analysis. | Baseline and one-week post-treatment/Week 9 for all participants, and post-treatment 1-month follow-up and post-treatment 6-month follow-up for the participants in the treatment groups | |
Secondary | Change in Objective Physiological Circadian Measures | Home-based dim-light melatonin onset assessment (expressed as time value hh:mm) is determined by 10-hour salivary melatonin collected at 30-minute intervals. | Baseline, one-week post-treatment/Week 9 | |
Secondary | Change in Daytime Sleepiness | Paediatric Daytime Sleepiness Scale (PDSS) is an 8-item self-rated scale measuring daytime sleepiness, ranging in total scores from 0 to 32 with higher scores indicating more sleepiness. | Baseline and one-week post-treatment/Week 9 for all participants, and post-treatment 1-month follow-up and post-treatment 6-month follow-up for the participants in the treatment groups | |
Secondary | Change in Daytime Fatigue | Multidimensional Fatigue Inventory (MFI) is a 20-item self-rated scale on fatigue symptoms. There are three subscales, measuring the physical (possibly scored from 7 to 35), mental (possibly scored from 6 to 30), and spiritual (possibly scored from 7 to 35), dimensions of fatigue. A grand total score can be calculated by summing up the three sub scores. In all cases, a higher score represents higher fatigue symptoms. | Baseline and one-week post-treatment/Week 9 for all participants, and post-treatment 1-month follow-up and post-treatment 6-month follow-up for the participants in the treatment groups | |
Secondary | Change in Quality of Life | KIDSCREEN-27 is a 27-item self-rated scale measuring health related quality of life measure for children and adolescents. There are five subscales on: physical well-being (possibly scored from 5 to 25), psychological well-being (possibly scored 7 to 35), autonomy & parents (possibly scored 7 to 35), peers & social support (possibly scored 4 to 20), and school environment (possibly scored 4 to 20). A grand total score can be calculated by summing up the five sub scores. In all cases, a higher score represents higher perceived well-being. | Baseline and one-week post-treatment/Week 9 for all participants, and post-treatment 1-month follow-up and post-treatment 6-month follow-up for the participants in the treatment groups |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05114824 -
Acceptability and Feasibility of an 8-week Online Mindfulness-Based Cognitive Therapy Program Among Undergraduate Students
|
N/A | |
Not yet recruiting |
NCT05958940 -
BioClock: Bright Light Therapy for Depressive Disorders
|
N/A | |
Completed |
NCT03556735 -
Pulsed Electro Magnetic Fields (PEMF) in Depression
|
N/A | |
Completed |
NCT04916548 -
Repeated Neurocognitive Measurements in Depressed Patients
|
Phase 1/Phase 2 | |
Recruiting |
NCT05767073 -
LIVES: Personalized Lifestyle Intervention for Patients With Depression
|
N/A | |
Completed |
NCT06094907 -
Safety, Tolerability and Antidepressant Effects of DMT in Patients With Depression
|
Phase 2 | |
Completed |
NCT04121091 -
Pramipexole to Target "Anhedonic Depression"
|
Phase 2 | |
Enrolling by invitation |
NCT03847688 -
Machine Learning to Predict Clinical Response to TMS
|
||
Completed |
NCT02945735 -
Gaze Contingent Feedback in Major Depressive Disorder (MDD)
|
N/A | |
Recruiting |
NCT06139159 -
CRISOL Mente: A Multilevel Community Intervention to Reduce Mental Health Disparities Among Latinos
|
N/A | |
Recruiting |
NCT05011864 -
Integrated Tele-Behavioral Activation and Fall Prevention for Low-income Homebound Seniors With Depression
|
N/A | |
Terminated |
NCT03537547 -
Combinatorial Pharmacogenomics Testing in Treatment-Naïve Major Depressive Disorder
|
Phase 4 | |
Completed |
NCT03515733 -
PF-04995274 and Emotional Processing in Treatment Resistant Depression
|
Phase 1 | |
Not yet recruiting |
NCT05991232 -
Repeated Neurocognitive Measurements in Depressed Patients
|
Phase 1/Phase 2 | |
Completed |
NCT03516604 -
PF-04995274 and Emotional Processing in Un-medicated Depression
|
Phase 1 | |
Completed |
NCT03538275 -
Chronobiology and Depression: Circadian Analytics as a Biomarker for Depressive Subtypes
|
||
Active, not recruiting |
NCT03096886 -
Novel Neural Circuit Biomarkers of Major Depression Response to CCBT
|
N/A | |
Not yet recruiting |
NCT06462196 -
Natural History of Depression, Bipolar Disorder and Suicide Risk
|
||
Completed |
NCT01874951 -
Low-Dose Naltrexone for Depression Relapse and Recurrence
|
Phase 2 | |
Completed |
NCT03906175 -
Whole-body Hyperthermia for Mild to Moderate Depressive Disorder
|
N/A |